^
Association details:
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
Source:
Published date:
09/08/2020
Excerpt:
…NCCN Panel has included taxanes (paclitaxel), anthracyclines (doxorubicin and liposomal doxorubicin), anti-metabolites (capecitabine and gemcitabine), microtubule inhibitors (eribulin and vinorelbine), platinum agents for patients with triple negative tumors and germline BRCA 1/2 mutations.